No change is a good thing when a disease once meant certain decline.
For generations, amyloidosis arrived quietly — a tingling in the fingers, a stiff shoulder, a heart slowly losing its rhythm — and by the time it was named, little could be done. That story is changing. New FDA-approved therapies can now halt the disease's progression, and for patients like Pennsylvania musician Bob DiCola, early detection and treatment have transformed a diagnosis once measured in months into a life still fully lived. The central challenge is no longer therapeutic but human: whether patients and physicians will recognize the whispers before the silence sets in.
- Amyloidosis disguises itself for years as carpal tunnel, joint pain, or nerve damage — by the time the heart is visibly failing, the disease has often been misdiagnosed across multiple specialists for more than two years.
- The stakes are severe: hereditary ATTR amyloidosis carries a 2.5–4 year life expectancy once cardiovascular symptoms appear, while AL amyloidosis can claim lives in under six months even with treatment.
- Three FDA-approved therapies now exist to stop disease progression, including vutrisiran — a quarterly injection that reduces the body's production of the misfolding protein by roughly 90% — with experimental 'depleter' drugs aiming to remove deposits already embedded in tissue.
- For Bob DiCola, a musician whose hands first signaled the disease, treatment has stabilized his condition over the past year with minimal side effects, allowing him to walk beaches and ride his bicycle without limitation.
- Genetic screening is now recommended for families carrying hereditary forms, as early intervention — before symptoms emerge — offers the possibility of a normal life expectancy, making awareness the most urgent medicine of all.
Bob DiCola first noticed it in his fingers — a tingling that a lifelong musician could not afford to ignore. His hands had kept time with polka bands across Pennsylvania for seven decades, and even a subtle change in grip felt like a warning. What followed was years of misdiagnosis: a pinched nerve, autoimmune suspicion, then a rare lymphoma that seemed to explain the symptoms but didn't explain everything. Only when a cardiac evaluation revealed an enlarged heart, confirmed by imaging and biopsy, did the full picture emerge. DiCola had cardiac amyloidosis — the same disease that had killed his brother John in 2022.
Amyloidosis occurs when the body's naturally produced amyloid protein misfolds and accumulates in tissues and organs. In its cardiac form, deposits stiffen the heart muscle and impair its ability to pump blood. The disease is deceptive: it rarely begins in the heart. Instead, it surfaces through tingling extremities, carpal tunnel syndrome, spinal stenosis, rotator cuff injuries, and unexplained drops in blood pressure — symptoms that appear years before the heart shows signs of failure. By the time a cardiologist is involved, the disease has often been fragmented across specialists who never connected the pieces.
DiCola's cardiologist, Daniel Davies of Allegheny Health Network, sees this pattern constantly. The two most common forms in the United States carry grim timelines: hereditary ATTR amyloidosis, the genetic variant DiCola carries, typically allows two and a half to four years after cardiovascular symptoms appear; AL amyloidosis is more aggressive, with patients in heart failure often surviving less than six months even with treatment.
For decades, amyloidosis was considered a death sentence. That began to shift in 2019 with the first FDA-approved therapies designed to slow or stop progression. DiCola now receives vutrisiran, a quarterly injection approved in 2025 that reduces transthyretin protein production in the liver by roughly 90%. Less protein produced means less available to misfold and accumulate. Researchers are also developing 'depleter' drugs that may help the immune system remove deposits already embedded in tissue — a potential leap beyond simply halting new damage.
For DiCola, treatment has brought stability. Over the past year, imaging has shown no significant changes. He walks the beach near his Delaware vacation home, rides his stationary bicycle each morning, and reports no sense of limitation. Side effects have been minimal — a day or two of sluggishness after injections. 'I've never felt sick,' he says.
Davies stresses that awareness remains the greatest obstacle to early diagnosis. Active older adults often attribute symptoms to aging, and unlike many cardiovascular conditions, amyloidosis cannot be prevented through lifestyle changes. For families with hereditary forms, genetic screening is essential even for relatives without symptoms. DiCola's family has been tested: one sibling carries the gene without developing disease; one daughter also carries it. Carrying the gene does not guarantee the disease will manifest — but knowing offers the chance to act before the heart begins to fail.
The message Davies delivers is direct: caught early and treated promptly, amyloidosis patients can achieve the same life expectancy as those without the disease. DiCola hopes his story helps others recognize the early signals — the tingling, the unexplained joint problems, the subtle changes that seem unrelated until someone pauses to connect them. The question is no longer whether amyloidosis can be treated. It is whether it will be found in time.
Bob DiCola felt it first in his hands—a tingling in his fingers that seemed small enough to ignore, except he couldn't. For seventy years, his hands had kept time with bands across Pennsylvania and beyond, the Pittsburgh PolkaMeisters, Miss Freddye in Philadelphia. Even the slightest change in grip registered as a threat. He went to his doctor looking for answers.
What followed was a diagnostic odyssey that would stretch across years and multiple false leads. His primary care physician started with the obvious suspects: a pinched nerve, a back injury, something orthopedic. An electromyograph confirmed neuropathy—nerve damage—but offered no explanation for its cause. Autoimmune disease was considered. Then blood work revealed something else entirely: a rare lymphoma, a real condition that could also cause the tingling in his extremities. It seemed like an answer, except it wasn't the whole answer. Only when a routine cardiac evaluation showed an enlarged heart, followed by imaging and a heart biopsy, did the true picture emerge. DiCola had cardiac amyloidosis, a disease his brother John had died from in 2022.
Amyloidosis occurs when amyloid protein, naturally produced by the body, becomes unstable and misfolds. These misfolded proteins accumulate in tissues and organs, and in the cardiac form, they deposit within the heart muscle itself, causing it to stiffen and lose its ability to pump blood effectively. The disease is insidious because it rarely announces itself through the heart first. Instead, it whispers through the body in other ways—tingling fingers, carpal tunnel syndrome that doesn't come from typing, spinal stenosis, rotator cuff injuries, unexplained drops in blood pressure, irregular heartbeats. Patients develop these symptoms years, sometimes decades, before their hearts begin to fail. By the time a cardiologist sees them, the disease has often been misdiagnosed, dismissed as aging, or fragmented across multiple specialists who never connect the pieces.
DiCola's cardiologist, Daniel Davies, medical director of Allegheny Health Network's cardiac amyloidosis program, sees this pattern constantly. It is not uncommon, he explains, for patients to wait more than two years after their first symptoms before receiving a correct diagnosis. The disease has roughly forty identified forms worldwide, though two dominate in the United States. DiCola carries the hereditary variant, hereditary ATTR amyloidosis, a genetic form involving the transthyretin protein. For people with this type, once cardiovascular symptoms appear, life expectancy is typically between two and a half to four years. The other common form, AL amyloidosis, is even more aggressive—patients presenting with heart failure symptoms often live less than six months, even with treatment.
For decades, amyloidosis carried a reputation as a death sentence because physicians had few tools to fight it. That began to shift in 2019 when the FDA approved the first therapies designed to slow or stop the disease's progression. Today, three FDA-approved medications exist. DiCola receives vutrisiran, a quarterly injection approved in 2025 that works by dramatically reducing the production of transthyretin protein in the liver. The effect is striking: about ninety percent of the protein no longer gets produced. When less protein is manufactured, less of it can misfold and deposit throughout the body. Researchers are also studying a new class of drugs called "depleters," designed not just to halt new protein accumulation but to help the immune system remove deposits already embedded in tissues.
For DiCola, the treatment has stabilized his disease. Over the past year, MRIs have detected no significant changes in his condition. He continues his regular treatments—immunotherapy every ninety days for the lymphoma, quarterly injections for amyloidosis—and remains active. He walks the beach near his Delaware vacation home, rides his stationary bicycle in the mornings, feels no limitation. The side effects are minimal: a bit of sluggishness, a passing headache for a day or two. "I've never felt sick," he says. "I've never felt limited in any way."
Davies emphasizes that awareness remains the greatest barrier to early detection. Many patients, especially active older adults, dismiss symptoms or attribute them to aging. A seventy-year-old with controlled blood pressure, no diabetes, who exercises five times a week can still develop carpal tunnel syndrome or spinal stenosis and, a couple of years later, notice increasing shortness of breath. Unlike many cardiovascular conditions, lifestyle changes do not prevent amyloidosis. For families carrying the hereditary form, genetic screening is critical, even for relatives without symptoms. DiCola's own family has undergone testing: one sibling carries the gene but has not developed disease; one of his daughters also carries the gene. But carrying the gene does not guarantee the disease will manifest.
Davies' message is urgent and clear: the earlier amyloidosis is detected and treatment begins, the better the outcome. If found and treated early, patients with amyloidosis can have the same life expectancy as others their age without the disease. DiCola hopes his story will help others recognize the early warning signs—the tingling, the unexplained joint problems, the subtle changes that seem unconnected until someone pauses and puts the pieces together. As awareness grows among both patients and physicians, and as more approved therapies with minimal side effects become available, the trajectory of this once-devastating disease is shifting. The question is no longer whether amyloidosis can be treated, but whether it will be caught in time.
Citas Notables
It's not uncommon that people aren't diagnosed with amyloidosis for more than two years after onset because symptoms appear at different times and aren't immediately connected.— Dr. Daniel Davies, cardiologist and medical director of Allegheny Health Network's cardiac amyloidosis program
The earlier we can find people and start them on therapy, by far the better that they're going to do. If found and treated early, those with amyloidosis have the exact same prognosis as somebody else their same age without this disease.— Dr. Daniel Davies
La Conversación del Hearth Otra perspectiva de la historia
What made you finally push for answers when so many doctors were telling you different things?
The tingling in my hands was real, and it was getting worse. As a drummer, I know my body. When something changes, you feel it. I wasn't going to accept "it's just aging" or "it's just a pinched nerve." I kept asking questions.
Your brother died from this disease. Did you suspect amyloidosis before the diagnosis?
Not really. I knew he'd been sick, but we didn't talk about it much. It wasn't until after my diagnosis that I understood what he'd gone through. That's when it hit me—this thing had already taken him from us.
The treatment you're on now, vutrisiran—it sounds almost miraculous. How does it feel to know you're getting ninety percent reduction in the protein?
Honestly, it feels like a second chance. A year ago, I didn't know if I'd be here. Now my MRIs show no change. No change is good. It means I'm not getting worse.
You're still dealing with lymphoma treatment on top of the amyloidosis injections. How do you manage all of that?
You just do it. The side effects are minimal—a little sluggishness, maybe a headache. It's nothing compared to what this disease could do. I ride my bike in the morning, walk on the beach. I'm living.
Your daughter carries the gene. What do you want her to know?
That having the gene doesn't mean it will happen. But she needs to be aware, to listen to her body, to get checked regularly. Early detection changes everything. That's what I've learned.
If you could tell someone who's experiencing tingling or joint problems right now, what would you say?
Don't wait. Don't let doctors dismiss it. Push for answers. Connect the dots yourself if you have to. This disease hides in plain sight, but if you catch it early, you can live a normal life. That's what I'm doing now.